The Target Of The Treatment In Non-Hodgkin's Lymphoma

Nowadays, cancer is one of the most serioustreatment is compromised by reducing the doses
problems in medicine.Specialists try to discoveror not respecting the schedule. So the chances of
new treatments. In clinics, the patients withlong-term survival and cure are influenced by the
cancer that start a new treatment are closelyway the treatments are being given.
followed. Physicians determine the optimal doseThere are some situations when reductions in
which have the minimal side effects and offersdoses of the treatment are unavoidable. This
the most numerous chances of survival. Becausehappens when there are older patients, or
doctors make often adjustments, the treatmentpatients with a higher stage of disease, patients
given to the patients does not always match withwho aren't able to care for themselves. in this
the treatment that studies found it to be thecircumstances the treatment have to be delayed
most effective. That's why sometimes peopletoo.
receiving the treatment doesn't feel very well,The best moment to give the appropriate
even if that treatment is supposed to save theirtreatment are the early stages of the disease.
life. If the patients have to get chemotherapy it isPreventative care is very important. Specifically
very important to respect the recommendedtreatment to boost low white blood cell counts
doses and schedule, and it is also important tocaused by chemotherapy, are more likely to
know the reasons why this rules are notreceive the dose on time and to receive fuller
respected.dose intensity than those patients who didn't
There are a lot of cases when different types ofreceive these agents. There many reasons,not
cancer, like breast cancer or even the Non-only cancer, for which patients received these
Hodgkin's lymphoma, are not correctly treatedmedications from the beginning.
and it is not given the appropriate supportiveAnother cause of under- treatment is the
therapy. It was proved that if those patientssituations when the patient doesn't tolerate the
were treated appropriately and the treatmentchemotherapy the way it was expected to be.
guidelines were followed, they would have a goodSo it increases the concern about side effects.
chance of survival and possible cure.There are situations when the reduction in dose
The Non- Hodgkin's lymphoma is a veryof the treatment is established from the very
aggressive type of cancer or the most commonbeginning, before the patient had received any
type of lymphoma. In lymphomas are affectedkind of treatment. This is a conscious decision of
the lymph glands and nodes that are anywhere inthe doctor who consult the patient and gets to
the body. So this kind of cancer can occurthe conclusion that he won't tolerate the
everywhere in the body. There is also a Hodgkin'schemotherapy well. Other reductions in doses of
disease that can often occur in younger patients.the treatment occurs after starting therapy,
The incidence of the Non- Hodgkin's lymphoma isbecause of the side effects. In this case reducing
bigger in older patients, most frequently aroundthe dose is a strategy to reduce the side effects
age 60, but latest it can occur in younger peopleof treatment. This has negative results because it
too. There is no explanation why this is one ofis very sure that to this patients the disease will
the cancers that affects more and morecome back months or years later.
individuals over the last 20 years.Supportive care is very important. Older patients,
Even if it is a very aggressive form of cancer it ispatients who have more intensive symptoms
very responsive in treatment and potentiallyfrom their disease or a higher stage of disease,
curable cancer, which is a resemblance with theneed a type of a more aggressive supportive
Hodgkin's disease. An appropriate treatment cancare. If they are supported in a right way it is
give the patients the chance to be cured and toalso recommended to be treated the same as
live a normal life. This is justified for more thanyounger patients are. This increases their chances
half of the patients.to be cured.When giving the supportive care it is
So it was proved that the aggressive disease isimportant to analyze the risk factors. This are the
more responsive to treatment which is a kind ofpatient's age that can easily lead to more side
a paradox which can be seen in many forms ofeffects or in the most cases determine the
rapidly growing cancers. The cells in this cancersphysician to reduce the doses or schedule of the
are rapidly dividing, but they tend to be moretreatment, even before starting it. Giving the right
responsive to treatment. The scientific explanationsupportive care enables the patients at a higher
for this phenomenon is that the chemotherapyrisk to receive the full treatment.
drugs are most active against rapidly growing cells.Supportive care helps physicians and patients with
The whole treatment in Non- Hodgkin's lymphomacancer to control nausea, vomiting and infections
can last for about four to five months. If there isthat can result because of the low white blood cell
an early stage disease, the patient may get acount. These are one of the most common side
shorter course of chemotherapy. This methodeffects of the toxicity of the chemotherapy.
must be combined with radiation therapy to theSupportive care includes treatments that can
affected area. Because the cancerous cells mayimprove the blood counts and also reduce the risk
be anywhere in the body the biggest part of theof infection. So if the patients seem not to
patients with cancer needs to be treatedtolerate the chemotherapy well, it is
systemically with chemotherapy. Chemotherapy isrecommended to use the supportive care and not
a combination of four or five drugs. The wholeto modify the doses and schedule in treatment.
treatment program can run over a period ofThis way the patient will be allowed to go through
about four to five months.the full program.
Even if this form of cancer is a curable one, thereThere are different kinds of treatments available
are people with Non-Hodgkin's lymphoma whoand it is very important for the patients recently
being under-treated.diagnosed Non- Hodgkin's lymphoma to ask an
This under- treatment means a substantial doseoncologist about the side effects of those
reductions or treatment delays during theirtreatments and what can be done to diminish and
chemotherapy. This is one of the reasons whyto prevent them. It is very important for this
some of this patients presents side effects andpatients to get the full treatment and to know
they don't get cured. It was proved in clinical trialsthat the target is to minimize side effects and to
that patients who receive the appropriateincrease the effects of the appropriate treatment.
treatment do better than patients whose